Impact of Visceral Fat on the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease

Visceral fat has been reported to be associated with nonalcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MetS). We assessed the prevalence of both NAFLD and the MetS, measured visceral fat thickness (VFT), and estimated the physical activity indexes of 224 relatively healthy hospital workers. We also investigated the associations between both VFT and physical activity index and each of NAFLD and the MetS. The MetS was diagnosed according to the guidelines outlined by the Adult Treatment Panel III, and NAFLD was diagnosed by ultrasonography. Subjects with hepatitis B and C infections and those reporting moderate alcohol consumption were excluded from the study. The prevalence of the MetS was 11.6% and that of NAFLD was 41.5%. Many subjects with the MetS had NAFLD (73.1%), and some subjects with NAFLD (20.4%) also had several components of the MetS (p=0.001). VFT was significantly increased by both the addition of components of the MetS and the severity of NAFLD (p<0.001). In addition, VFT was independently associated with NAFLD (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02-1.19) in subjects with more than 2 components of the MetS. In contrast, habitual physical activity was reversely associated with NAFLD (OR, 0.29; 95% CI, 0.10-0.87). In conclusion, an increased visceral fat content and reduced physical activity could be not only biological markers but also therapeutic targets in the treatment of NAFLD and the MetS.

Key Words: Nonalcoholic Fatty Liver Disease; Metabolic Syndrome; Intra-Abdominal Fat; Work Index

INTRODUCTION

The metabolic syndrome (MetS) is a clustering of metabolic risk factors, including abdominal obesity, high blood pressure (BP), high triglyceride (TG) levels, low levels of high-density lipoprotein (HDL) cholesterol, and high levels of fasting plasma glucose (1). The MetS is associated with subsequent increases in the incidence of type 2 diabetes mellitus (DM) (2), cardiovascular disease (CVD) morbidity (3) and even mortality (4).

The MetS is significantly associated with increased levels of alanine aminotransferase (ALT), a liver-specific enzyme (5). Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the MetS (6). The close relationship between the MetS and NAFLD might be attributable to an overaccumulation of stored fat in the abdomen and liver (7). A previous study showed that the prevalence of the MetS was influenced by an increase in physical activity (8). However, the previous studies only focused on the MetS (8) and were performed only in men (7) or in obese elderly subjects (9).

In the present study, we sought to determine the prevalence of NAFLD and the MetS, and to evaluate the distribution of NAFLD (and its grades of hepatic steatosis) according to the addition of the components of the MetS in relatively healthy hospital workers. We then investigated how visceral fat content and physical activity were associated with both NAFLD and the MetS in men and women.

MATERIALS AND METHODS

Study participants

Potential participants for this study were recruited in 2005 from a group of hospital workers aged 30 to 59 yr at Chonbuk National University Hospital, Jeonju, Jeonbuk, Korea. Age- and sex-stratified random cluster sampling was adopted for the selection of the study population. The hospital workers were comprised of 249 men and 529 women, and a total of 334 (43%) workers were randomly selected for participation in this study. All participants gave written informed consent, and the study was approved by the Chonbuk National University Hospital research ethics committee.
Data collection and measurement

The study was conducted by medical personnel from the hospital, all of whom were trained and supervised by physicians. A blood sample was obtained from each participant. All participants were interviewed using a questionnaire designed to determine whether there was a prior history of CVD, type 2 DM, hypertension, and medication usage. The questionnaire also included questions related to lifestyle, including alcohol-drinking status, as estimated by the frequency, duration, amount and type of liquor consumed. The mean ethanol intake per day was calculated from this data. The participants were divided into three groups according to smoking status: current smokers, ex-smokers, and non-smokers. Physical activity was investigated using Baecke’s Habitual Activity Questionnaire (10), which was translated into a Korean version and validated in a previous study (11). The Baecke’s questionnaire was divided into three indexes: 1) physical activity at work, work index; 2) athletic activity during leisure time, sports index; and 3) physical activity during leisure time excluding athletic activity, leisure time index.

Blood pressure was measured on the right arm with the subject in a sitting position using a standard mercury manometer after at least 5 min of rest. Two readings were obtained from each participant at 5 min intervals, and the mean value of the two readings was taken as the individual’s BP. Waist circumference (WC) was measured midway between the lower rib margin and iliac crest. Skinfold thickness was measured at the biceps, triceps, subscapular, and suprailiac skinfolds using a Skindex caliper (Skyndex I Electronic Fat Calipers, Caldwell, Justiss & Co., Inc., AR, U.S.A.). All measurements were performed twice, and the observers were supervised by a single trainer. The Durnin-Womersley formula was used to calculate the percentage of body fat (12), which was closely related to the amount of subcutaneous adipose tissue (13).

Blood samples were collected in the morning after an overnight fast. Serum samples were obtained after venous blood collection and centrifugation at 3,000 g for 15 min. Serum biochemistry analyses were performed on a Hitachi 7600-110 analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan). Both serum aspartate aminotransferase (AST) and ALT activities were measured according to the International Federation of Clinical Chemistry (IFCC) reference method (ASAN Pharmaceutical Co., Ltd, Seoul, Korea). γ-Glutamyl transferase (GGT) was measured using a modified IFCC method (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Serum TG, glucose and uric acid concentrations were determined enzymatically (Roche Diagnostics GmbH, Mannheim, Germany). HDL-cholesterol was measured enzymatically as cholesterol after selective disruption of HDL only (Daichi Pure Chemicals Co., Ltd., Tokyo, Japan). C-reactive protein (CRP) was determined by a latex agglutination immunoassay using antihuman CRP mouse mono-clonal antibody-coated latex (Daichi Pure Chemicals Co., Ltd.). The level of apolipoprotein B (apoB) was determined by a Roche/Hitachi Modular P Chemistry analyzer using an immunoturbidimetric assay (Roche Diagnostics GmbH). Serological markers of hepatitis B (HBsAg, anti-HBs) were determined by electrochemiluminescence immunoassay (MODULAR ANALYTICS E170, Roche Diagnostics GmbH), and anti-HCV status was determined using a chemiluminescent microparticle immunoassay (ARCHITECT, Abbot Laboratories, Abbot Park, IL, U.S.A.). Daily quality control of the above measurements made on Hitachi instruments was carried out at each site by duplicate measurements with a commercially available control material (Bio-Rad Laboratories, CA, U.S.A.). Assay performance was monitored regularly by the Korean Association of Quality Assurance for Clinical Laboratory and the Korean Society of Laboratory Medicine (KSLM) Laboratory Inspection and Accreditation Program (IAP) (14).

All ultrasonographic examinations were performed by one radiologist (Y.K.K) who had 9 yr of experience performing abdominal ultrasonography. The total number of sonograms performed by Y.K.K. has exceeded 5,000 per annum over the past 8 yr. The radiologist was blinded to the patients’ medical histories and their laboratory findings. For each subject, the severity of fatty liver disease was evaluated, and visceral fat thickness (VFT) was measured using a 3.5-MHz convex probe (Sequoia, Siemens Medical Solutions, Mountain View, CA, U.S.A.). The severity of fatty liver disease was subjectively rated by the radiologist based on the following three grading scales (15, 16): grade 1, a slight diffuse increase in fine echoes in the hepatic parenchyma with normal visualization of the diaphragm and intrahepatic vessel borders; grade 2, a moderate diffuse increase in fine echoes with slightly impaired visualization of the intrahepatic vessels and diaphragm; and grade 3, a marked increase in fine echoes with poor or no visualization of the intrahepatic vessel borders, diaphragm, and posterior portion of the right lobe of the liver. In addition to the severity of fatty liver disease, the examiner also assessed the evidence of chronic hepatitis or liver cirrhosis, including hepatic nodularity, coarseness of liver parenchyma, and splenomegaly. VFT was measured along the length of an imaginary vertical line between the posterior aspect of the anterior abdominal wall and anterior line of the abdominal aorta, at the mid-point between the transverse portion of the duodenum and the iliac bifurcation of the aorta. The level that was devoid of bowel or its contents was chosen for the measurement of VFT in order to obtain the purest possible measurement. To avoid any calculation bias, mean values of each of three measurements were acquired. Repeated measurements on the same subjects (12 men and 13 women) gave coefficients of variation (CV) of <1% for the severity of fatty liver disease and <6.5% for VFT.

The MetS was identified by the presence of three or more components of the MetS according to the Third Adults Treat-
ment Panel (ATP-III) of the National Cholesterol Education Program (NCEP) (1), with modified WC cutoff values for Asian populations (17): 1) abdominal obesity (WC ≥90 cm for men and ≥80 cm for women); 2) high TG (≥150 mg/dL); 3) low HDL-cholesterol (<40 mg/dL for men and <50 mg/dL for women); 4) high BP (≥130/85 mmHg or subjects using antihypertensives); and 5) high fasting glucose (≥110 mg/dL).

The exclusion criteria for NAFLD used in the present study were guided by a previous report (18): 1) an alcohol intake of more than 20 g/day, 2) seropositivity for hepatitis B surface antigen (HBsAg), 3) seropositivity for anti-hepatitis C virus antibody (anti-HCV), 4) a prior history of taking medications that could cause steatosis, including steroids, amiodarone, estrogens, etc, and 5) a prior history of any kind of liver disease. Finally, using the current exclusion criteria, we chose the subjects with NAFLD from among the participants with hepatic steatosis.

**Statistical analysis**

For all variables, the mean (±SD) or proportion was reported according to the number of MetS components. The variables were compared by analysis of variance (ANOVA) or χ² test for trend, as appropriate. A χ² test was performed to assess trends in the association between the grade of NAFLD and the number of MetS components. The mean values of VFT according to the grades of NAFLD were presented for each gender, and interaction terms was calculated by two-way ANOVA. According to the presence of NAFLD, independent t-test or χ² test was performed in the subjects with more than two components of the MetS because NAFLD was found markedly increased from the subjects with just two components. All independent variables that showed differences of more than borderline significance (p<0.1) for NAFLD were entered in a multivariate logistic regression model in order to determine the independent association with NAFLD. All statistical calculations were performed using Stata 8.2 software (Stata Corporation, College Station, TX, U.S.A.).

**RESULTS**

Among the eligible subjects (n=334), 135 men and 158 women completed the survey (response 87.7%). A total of 69 participants were excluded: 47 (14.1%) men reported consuming more than 20 g of alcohol per day, 11 (3.3%) were seropositive for hepatitis B antigen, and 5 (1.5%) were seropositive for anti-HCV antibody, one (0.3%) was a moderate alcohol drinker and HBsAg positive, and one (0.3%) was anti-HCV positive and an alcohol drinker. In addition, four participants (1.2%) were not subjected to an abdominal ultrasonographic examination, and two of them reported having a history of drug-induced liver disease. A total of 78 men and 146 women (67.1%) were included in the final analysis. The participants and non-participants did not differ

### Table 1. Characteristics of the subjects

| Characteristics                  | 0               | 1               | 2               | 3               | 4+              | p*               |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Number (%)                       | 70 (31.3)       | 73 (32.6)       | 55 (24.6)       | 18 (8.0)        | 8 (3.6)         | <0.001          |
| Age (yr)                         | 41.0 ±6.6       | 44.0 ±6.9       | 45.2 ±7.5       | 47.3 ±6.6       | 48.9 ±5.0       | <0.001          |
| Formal education (yr)            | 15.5 ±2.8       | 15.3 ±3.0       | 13.8 ±3.8       | 12.6 ±5.0       | 13.7 ±2.1       | 0.011           |
| Women (%)                        | 70.0            | 67.1            | 69.1            | 50.0            | 12.5            | 0.123           |
| Smoking, ex- and current (%)     | 21.7            | 26.4            | 21.8            | 50.0            | 37.5            | 0.091           |
| Alcohol non-drinker (%)          | 40.0            | 43.5            | 36.4            | 44.4            | 50.0            | 0.845           |
| Having past medical history (%)  | 4.3             | 6.8             | 14.5            | 44.4            | 37.5            | <0.001          |
| ALT (IU/L)                       | 18.5 ±9.1       | 20.3 ±9.5       | 22.4 ±14.1      | 31.7 ±21.2      | 35.6 ±21.1      | <0.001          |
| AST (IU/L)                       | 19.8 ±4.0       | 20.7 ±5.9       | 20.5 ±5.7       | 24.7 ±8.8       | 27.8 ±8.7       | <0.001          |
| GGT (IU/L)                       | 16.0 ±9.4       | 19.9 ±12.7      | 19.8 ±15.9      | 27.3 ±17.8      | 26.9 ±10.5      | 0.009           |
| Uric acid (mg/dL)                | 4.6 ±1.4        | 4.7 ±1.4        | 5.0 ±1.1        | 6.0 ±1.8        | 6.7 ±1.0        | <0.001          |
| ApoB (g/L)                       | 0.7 ±0.2        | 0.8 ±0.3        | 0.8 ±0.2        | 0.9 ±0.2        | 1.0 ±0.2        | <0.001          |
| C-reactive protein (mg/L)        | 0.5 ±1.5        | 0.8 ±2.0        | 0.8 ±1.5        | 1.9 ±2.2        | 1.2 ±1.8        | <0.001          |
| Visceral fat thickness (cm)      | 22.9 ±10.3      | 25.5 ±10.7      | 31.2 ±12.1      | 37.2 ±15.5      | 53.5 ±25.7      | <0.001          |
| Durnin-Womersley body fat (%)    | 23.9 ±3.9       | 25.9 ±4.4       | 27.9 ±3.8       | 27.1 ±3.5       | 25.6 ±4.0       | <0.001          |

Mean ± standard deviation (SD) was expressed, unless noted otherwise.

* p values by analysis of variance (ANOVA) or χ² test for trend; † Past medical history included hypertension, type 2 DM, or dyslipidemia; ‡ Back transformed data of logarithmic transformation of original C-reactive protein were presented. MetS, metabolic syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; ApoB, apolipoprotein B.
fer significantly with respect to age (mean ± SD, 43.8 ± 7.2 and 43.6 ± 7.3 yr, respectively). However, the participants included more women than the non-participants (65.2 and 17.4%, p < 0.001).

The MetS was observed in 26 subjects (11.6% in total, 20.5% and 6.8% in men and women, respectively, p = 0.002), as shown in Table 1. There were 70 subjects with no component of the MetS, 73 with one, 55 with two, 18 with three, and 8 with four or more MetS components (31.3, 32.6, 24.6, 8.0, and 3.6%, respectively). VFT increased significantly with the addition of components of the MetS (p < 0.001). In addition, age, past medical history, AST, ALT, GGT, apoB, uric acid, and Durnin-Womersley percent body fat were also significantly increased with the addition of MetS components. The proportion of women and years of formal education decreased significantly with the addition of MetS components. There were no significant changes in smoking, alcohol non-drinking, CRP, and Baecke's physical activity indexes.

VFT increased significantly according to the severity of NAFLD in both sexes (p < 0.001, Fig. 1). Even though VFT was much greater in men than in women for all grades of hepatic steatosis, the interaction terms between sex and grade of NAFLD was not significant (p = 0.303, R² = 0.627).

The severity and incidence of NAFLD was significantly associated with the addition of MetS components, as shown in Table 2 (p < 0.001). NAFLD was observed in 41.5% of the subjects (57.7% and 32.9% in men and women, respectively, p < 0.001). Many subjects with the MetS had NAFLD (73.1%), and components of the MetS were present in 20.4% of the subjects with NAFLD (p = 0.001). Thirty-six of the

![Graph showing distribution of visceral fat thickness according to the grade of NAFLD in subjects with more than 2 components of the metabolic syndrome. Visceral fat thickness was significantly increased with the severity of NAFLD (p < 0.001). The interaction terms between gender and the severity of NAFLD were not significant (p = 0.303).]

**Table 2. NAFLD according to the addition of components of the MetS.**

| Grading of NAFLD | Addition of MetS components (no, %) | Total  |
|-----------------|-------------------------------------|--------|
|                 | 0                                   | 1      | 2      | 3      | 4+     | 131    |
| 0               | 57 (81.4)                           | 48 (65.8) | 19 (34.5) | 7 (38.9) | 0 (0.0) | 131    |
| 1               | 10 (14.3)                           | 18 (24.7) | 26 (47.3) | 2 (11.1) | 2 (25.0) | 58     |
| 2               | 2 (2.9)                             | 6 (8.2)   | 7 (12.7)   | 6 (33.3)  | 3 (37.5) | 24     |
| 3               | 1 (1.4)                             | 1 (1.4)   | 3 (5.5)     | 3 (16.7)  | 3 (37.5) | 11     |
| Total           | 70                                  | 73      | 55       | 18      | 8       | 224    |

p < 0.001 by χ² test for trend.  
NAFLD, nonalcoholic fatty liver disease; MetS, metabolic syndrome.

![Graph showing distribution of VFT according to the grade of hepatic steatosis, NAFLD. Visceral fat thickness (VFT) increased significantly according to the severity of NAFLD (p < 0.001). The interaction terms between sex and grade of NAFLD were not significant (p = 0.303).]

**Table 3. Characteristics of the subjects with more than 2 components of the MetS according to the presence of NAFLD.**

| Characteristics | Absent (n=26) | Present (n=55) | p*  |
|-----------------|--------------|---------------|-----|
| Age (yr)        | 47.5 ± 7.6   | 45.3 ± 7.0    | 0.214 |
| Formal education (yr) | 13.0 ± 4.9   | 13.7 ± 3.5    | 0.539 |
| Women (%)       | 73.1         | 52.7          | 0.082 |
| Smoking, ex- and current (%) | 19.2 | 34.5 | 0.159 |
| Alcohol non-drinker (%) | 53.8 | 32.7 | 0.070 |
| Menopause (%)   | 52.6 (10)    | 37.9 (11)     | 0.315 |
| Smoking history  | 26.9         | 21.8          | 0.613 |
| Waist circumference (cm) | 81.0 ± 7.2   | 87.3 ± 7.4    | 0.001 |
| Systolic blood pressure (mmHg) | 116.9 ± 18.1 | 122.5 ± 14.5 | 0.137 |
| Diastolic blood pressure (mmHg) | 77.6 ± 10.8  | 79.2 ± 10.1   | 0.530 |
| Triglyceride (mg/dL) | 121.1 ± 52.4 | 166.1 ± 86.4 | 0.017 |
| HDL cholesterol (mg/dL) | 43.0 ± 5.6   | 41.4 ± 9.2    | 0.426 |
| Fasting blood glucose (mg/dL) | 93.7 ± 11.3  | 97.4 ± 19.8   | 0.368 |
| ALT (IU/L)       | 18.2 ± 9.9   | 29.3 ± 18.7   | 0.001 |
| AST (IU/L)       | 19.5 ± 4.6   | 23.4 ± 7.8    | 0.006 |
| GGT (IU/L)       | 16.5 ± 10.6  | 24.8 ± 17.6   | 0.010 |
| ApoB (g/L)       | 0.81 ± 0.16  | 0.90 ± 0.21   | 0.056 |
| Uric acid (mg/dL) | 5.0 ± 1.3    | 5.6 ± 1.4     | 0.062 |
| C-reactive protein (mg/L) | 1.2 ± 0.2    | 1.0 ± 1.6     | 0.437 |
| Visceral fat thickness (cm) | 24.6 ± 9.3   | 39.5 ± 16.2   | < 0.001 |
| Durnin-Womersley body fat (%) | 27.4 ± 4.0   | 27.6 ± 3.7    | 0.832 |

Mean ± SD was expressed; unless noted otherwise.  
*, p values by independent t-test or χ² test.  
1. Past medical history means hypertension, type 2 DM, or dyslipidemia;  
2. Back transformed data of logarithmic transformation of original C-reactive protein were presented.  
NAFLD, Nonalcoholic fatty liver disease; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; apoB, apolipoprotein B.
subjects with two MetS components (65.5%) had NAFLD, and 19 (73.1%) of the subjects with more than three components of the MetS also had NAFLD. None of the patients with more than 4 components of the MetS had a normal liver. None of the patients showed any evidence of chronic hepatitis or liver cirrhosis, such as hepatic nodularity, on ultrasonography.

In the subjects with more than two components of the MetS, WC, TG, ALT, AST, GGT, and VFT, were significantly higher in the group of patients with NAFLD than the group without NAFLD (Table 3). In addition, the patients with NAFLD had significantly lower work index scores. Female gender, alcohol non-drinking, apoB, and uric acid showed borderline significance ($p<0.1$). After adjustment for all potential confounders, NAFLD was independently and positively associated with VFT (OR, 1.10 [95% CI, 1.01-1.19]) and inversely associated with work index (0.29 [0.10-0.87]) (Table 4).

**DISCUSSION**

This study shows that increased visceral fat content is significantly associated with both NAFLD and the MetS and that there is a significant linear trend in the grade of hepatic steatosis and components of the MetS. Increased VFT can be a common denominator of both NAFLD and the MetS because VFT showed an independent association with NAFLD, even in the subjects with more than two components of the MetS. In addition, the negative association between an increase in physical activity and NAFLD suggests that physical activity in occupational environments may have therapeutic effects on patients with NAFLD. There has been no previous report showing the associations between both VFT and physical activity and each of NAFLD and the MetS.

The amount of VFT was independently associated with NAFLD after adjustment for potential confounders. Even the absolute amounts of VFT were different in both sexes: VFT increased linearly according to both the grade of hepatic steatosis (Fig. 1) and the number of MetS components (Table 1) in both men and women. Considering the pathophysiologic roles of fatty acids and their accumulation in nonadipose tissue, VFT seemed to be directly associated with the development and progression of NAFLD and the MetS. The accumulation of fat causes excessive oxidative stress (19), increases the level of plasminogen activator inhibitor type 1 (20), increases hepatic glucose production (21, 22), and down-regulates adiponectin production (23).

WC lost significance when VFT and WC were entered simultaneously into the multivariate model. The finding was similar to that of the previous reports in which WC was not an independent predictor of NAFLD (24), and abdominal obesity defined by large WC was the least predictive factor for the MetS (6). WC was simple to measure and interpret, and it has been shown to be consistently associated with dyslipidemia in a Korean population (25); however, care should be taken when choosing a more sensitive and predictive representation of abdominal obesity. In the present study, VFT was measured along the midline of the body as an indication of fat thickness. Although there was no account of total abdominal fat content, the results of our study suggest that ultrasonography-guided midline VFT measurement could be a better indicator of visceral obesity than WC.

The work index, an indicator of habitual physical activity at work (standing, sitting, heavy loading, sweating, and so on), was inversely associated with NAFLD, as shown in Table 3, 4. Abdominal fat was preferentially used during muscle exercise (9). In addition, a heavier workload is known to enhance peripheral fatty acid consumption, reduce TG accumulation in the liver, and finally improve insulin resistance, as the authors of a previous study reported an association between TG and insulin resistance via endoplasmic reticulum stress (26).

The prevalence of NAFLD was 41.5% in the present study. The prevalence of ultrasonographically diagnosed NAFLD among 401 Korean subjects who visited the hospital for routine physical exams was 27.2%, which was lower than the present result (27). A study investigating hepatic steatosis in northern Italy reported that the prevalence of steatosis diagnosed by ultrasonography in control and obese subjects was 45.9% (28). A report from the Dionysos study group did not directly show the prevalence of NAFLD, but suggested that it might be more than 32.8% after excluding the subjects with alcoholic fatty liver, hepatitis B and C infections (24). The prevalence of NAFLD reported by a recent study was 18%, even though the study was not originally designed for the detection of NAFLD (29).

In the present study, many subjects with the MetS had NAFLD (73.1%), and components of the MetS were present in 20.4% of the subjects with NAFLD. This unique trend of association between NAFLD and the MetS was similar to that described in the previous report, which showed that NAFLD was present in 58.9% of the patients with the MetS and that the MetS was present in 36.8% of patients with NAFLD (29). The reason why the former ratio (NAFLD in the MetS) was higher than the latter ratio (the MetS in NAFLD) might be due to a difference in detection methods.
NAFLD refers to a state of increased hepatic steatosis without considering other metabolic factors. Actually, first grade hepatic steatosis was beginning to occur in the subjects with only two metabolic components, and not in those with more than 3 components of the MetS, as shown in Table 2, which indicated that hepatic steatosis might be an early manifestation of visceral obesity rather than the MetS.

The present study has several limitations. First, there was a large discrepancy between the prevalence of the MetS in our previous report (5) and that in the present study (23.8% and 11.6%, respectively). This discrepancy might be due to the difference in the degree of formal education received by the subjects because education is known to affect the prevalence of obesity and related cardiovascular diseases (30). In the previous report, only 52% of the subjects had received more than 1 yr of formal education, whereas the present subjects had received about 14 yr of education, as shown in Table 1. Another limitation of this study is that NAFLD was diagnosed using ultrasonography in the present study. The limitations of ultrasonography in the detection of fatty liver disease with the purpose of research were sufficiently described in previous reports (16, 24, 28). The sensitivity of ultrasonography for the diagnosis of fatty liver disease has been reported to be somewhat low, but the specificity has been reported to be high (31). However, superior noninvasive methods of ultrasonography have not been reported (32), and invasive methods, such as liver biopsy, are not suitable for use in epidemiologic studies. A third limitation is that the present study was designed to be cross-sectional, so we could not determine whether or not NAFLD was precedent to the MetS. However, the high incidence of first grade hepatic steatosis in subjects with two metabolic components suggested the possibility of an earlier manifestation of the NAFLD resulting in visceral fat accumulation before the MetS was evident. Finally, the results of the present study cannot be applied directly to general populations because it was designed for and performed in a population of hospital workers.

In conclusion, VFT was significantly associated with both the severity of hepatic steatosis in NAFLD and the addition of components of the MetS. The measurement of increased VFT and estimation of the amount of physical activity could be not only a biological markers but also therapeutic targets in the treatment of both NAFLD and the MetS. A comprehensive study, including medical and social activity, concerning this issue is warranted.

ACKNOWLEDGMENTS

We, the authors, would like to extend special thanks to Cho MH and Lee JH, and Kim JH for their valuable assistance in the study processes and preparation of this manuscript. This work was supported in part by a grant from the Korean Stroke Society Young Investigator’s Award (KSS-2006-002).

REFERENCES

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-7.
3. Onut A, Ceyhan K, Basar O, Ezer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-92.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahtti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
5. Jeong SK, Nam HS, Rhee JA, Shin JH, Kim JM, Cho KH. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obes Relat Metab Disord 2004; 28: 1033-8.
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
7. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005; 22: 1354-8.
8. Ford ES, Kohl HW 3rd, Mokdad AH, Ajani UA. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obes Res 2005; 13: 608-14.
9. O’Leary VB, Marchetti CM, Krishnan RK, Stetzer BP, Gonzalez F, Kirwan JP. Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol 2006; 100: 1584-9.
10. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36: 936-42.
11. Lee CW, Lee SH, Lee MS, Suh SK, Yoon NK, Ahn EJ. Measurement properties of Baecke’s habitual physical activity questionnaire and related variables. J Korean Pub Health Asso 1992; 18: 38-53.
12. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974; 32: 77-97.
13. Andrade S, Lan SJ, Engelson ES, Agin D, Wang J, Heymsfield SB, Kotler DP. Use of a Durnin-Womersley formula to estimate change in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr 2002; 75: 587-92.
14. Lee WG, Kwak YS, Lee DH, Hwang YS, Lee KN. Laboratory inspection and accreditation in Korea II: analysis of the first round inspection. Korean J Lab Med 2003; 23: 363-9.
15. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol 1985; 145: 753-5.
16. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
18. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004; 3: 63-5.
19. Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, Achten R, Verslype C, Diehl AM. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003; 163: 1301-11.
20. Banfi C, Mussoni L, Ris P, Cattaneo MG, Vicentini L, Battaini F, Galli C, Tremoli E. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res 1999; 85: 208-17.
21. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J Biol Chem 2004; 279: 52345-53.
22. Barzilai N,She L, Liu BQ, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48: 94-8.
23. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.
24. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
25. Jeong SK, Seo MW, Kim YH, Kweon SS, Nam HS. Does waist indicate dyslipidemia better than BMI in Korean adult population? J Korean Med Sci 2005; 20: 7-12.
26. Kim DS, Jeong SK, Kim HR, Kim DS, Chae SW, Chae HJ. Effects of triglyceride on ER stress and insulin resistance. Biochem Biophys Res Commun 2007; 363: 140-5.
27. Kim SY, Shim KW, Lee HS, Lee SH, Kim HL, Oh YA. The association between nonalcoholic fatty liver disease with metabolic syndrome. J Korean Acad Fam Med 2007; 28: 667-74.
28. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
29. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fuji K, Omatsu T, Nakajima T, Sazui H, Shimazaki M, Kato T, Okada J, Iida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
30. Woo J, Leung SS, Ho SC, Sham A, Lam TH, Janus ED. Influence of educational level and marital status on dietary intake, obesity and other cardiovascular risk factors in a Hong Kong Chinese population. Eur J Clin Nutr 1999; 53: 461-7.
31. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139: 43-50.
32. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.